In accordance with the provisions of Regulation 30 of the SEBI Listing Regulations and SEBI’s circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015, Piramal Enterprises has informed that the Company’s Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania. The transaction closure is subject to customary pre-closing conditions. According to the terms of the agreement, Piramal Enterprises (‘PEL’), through one of its Affiliates, would acquire at closing a 100% stake in G&W PA Laboratories LLC (‘G&W PA’) in an all-cash deal for a total consideration of USD 17.5 million. G&W PA was formed on November 5, 2014. The transaction is not subject to any regulatory approvals. No related party of PEL has any interest in G&W PA. The company has enclosed a press release being issued in this regard.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Bajaj Finance | 955.05 |
| Shriram Finance | 1007.95 |
| Aditya Birla Capital | 363.05 |
| Chola Invest & Fin. | 1676.05 |
| Tata Capital | 321.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: